GlassScriptPhysician profile
Prabhakar Rumalla
NPI 1669404943
$4,909.77
in general payments reported to CMS, 2019-2025
26 companies · $524 in 2025
The $524 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $412 · 2021: $853 · 2022: $990 · 2023: $459 · 2024: $1,039 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,927.34 | 2019-2025 | Creon, Rinvoq, Linzess |
| Boston Scientific Corporation | $341.61 | 2020-2024 | Resolution 360 Clip |
| Gilead Sciences, INC. | $315.55 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $285.20 | 2024-2025 | Voquezna |
| Stryker Corporation | $253.05 | 2021 | |
| Janssen Biotech, INC. | $249.76 | 2022-2025 | Stelara, Tremfya, Simponi |
| Nestle Healthcare Nutrition INC. | $209.47 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.36 | 2022-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $125.79 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $124.46 | 2022 | |
| Madrigal Pharmaceuticals | $111.94 | 2024 | Rezdiffra |
| Celgene Corporation | $98.52 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $98.39 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.83 | 2019-2024 | Xifaxan |
| Lucid Diagnostics INC. | $87.57 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $75.20 | 2022 | |
| Aimmune Therapeutics, INC. | $74.58 | 2024 | |
| Medtronic, INC. | $58.03 | 2021-2025 | Pillcam |
| Braintree Laboratories, INC. | $53.32 | 2019 | |
| Pfizer INC. | $46.22 | 2019-2020 | |
| Vivus LLC | $38.19 | 2021-2022 | |
| Organon LLC | $21.77 | 2024 | |
| Celltrion USA INC. | $21.47 | 2024 | Zymfentra |
| Regeneron Healthcare Solutions, INC. | $17.84 | 2022 | |
| Pharming Healthcare, INC. | $13.16 | 2020 | |
| Intercept Pharmaceuticals, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhakar Rumalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.